AbCellera Biologics: Q3 Commentary - Moving Up The Value Stack

Nov. 09, 2022 1:45 AM ETAbCellera Biologics Inc. (ABCL)LLY, REGN61 Comments
Confoundedinterest profile picture
Confoundedinterest
7.65K Followers

Summary

  • AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines.
  • The company, in the days before the release, indicated that Regeneron has advanced its first GCPR target into preclinical development, further validating its platform.
  • The company's proprietary suite of T-cell engagers, billed as the world's largest and the internal GCPR effort, continues to develop and may offer compelling partnership opportunities in the near future.
  • The company's currently marketed COVID antibody is unlikely to be useful against new, emerging variants, however, the company announced yet another bullet in the chamber.
  • The company is flush with cash and is fully funded for the completion of its CNC/GMP facility expected in 2024, which will provide meaningful acceleration and revenue potential to partnered programs.

Female Research Scientist with Bioengineer Working on a Personal Computer with Screen Showing Virus Analysis Software User Interface. Scientists Developing Vaccine, Drugs and Antibiotics in Laboratory

gorodenkoff

Many long-time followers of mine are familiar with my rather outsized long position in AbCellera Biologics (ABCL). Currently, it makes up a whopping 46% of my speculative portfolio; and as such, when they report, I tend to pay very

Molecules in the clinic

AbCellera

Co-development

AbCellera

Internal Programs

AbCellera

Partners

AbCellera

This article was written by

Confoundedinterest profile picture
7.65K Followers
I work in the financial and property management industry for a well known, publicly traded "mini Berkshire" Insurance company. I focus on portfolio structure, value, reasonably priced growth, tech and biotech spaces. I passed the series 6 and 7 exams at age 18 but do not at this time have active licenses. I am not a licensed financial advisor and do not give out or publish investment advice. Articles I write are my opinion only and are not solicitations, please seek guidance from a licensed financial advisor before investing in any security. Opinions expressed in my articles are my own and do not reflect or indicate any positions or opinions held of my primary employer.

Disclosure: I/we have a beneficial long position in the shares of ABCL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I am not a licensed financial advisor. This is not a solicitation to buy or sell a specific security nor is it to be construed as investment advice, please contact your licensed financial and tax advisor for advice on your specific situation. This article is an opinion piece only and should not be construed as fact or be represented as such, please perform your own due diligence prior to investing in this or any equity.

Recommended For You

Comments (61)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.